Could kids with rare bone disease need less medicine?
NCT ID NCT07183579
Summary
This study is looking back at the medical records of children with a rare bone disease called XLH. The goal is to see if a lower starting dose of the standard treatment drug, burosumab, works just as well as the current higher standard dose to control blood phosphate levels. Researchers will review data from about 120 children across England to help doctors find the most effective and possibly more cost-efficient dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED HYPOPHOSPHATEMIA (XLH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nottingham University Hospitals NHS Trust
RECRUITINGNottingham, NG7 2UH, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.